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period, FAST scores were signiﬁ cantly correlated with individual symptoms, impact
on daily activities and sleep, and ﬂ ushing-related dissatisfaction (p  0.01). Changes 
in FAST scores were associated with treatment satisfaction (p  0.01) and patient/phy-
sician-rated OTE (p  0.01). Responders, deﬁ ned by improved OTE ratings, experi-
enced greater improvements than non-responders (p  0.01) in maximum (1.85 points 
vs. 0.18 points) and mean (0.51 points vs. 0.15 points) overall ﬂ ushing severity
scores. Among patients with ﬂ ushing, mean FAST scores differed between those who 
subsequently discontinued due to ﬂ ushing (7.9/10 points) vs. those who did not (4.7/10
points; p  0.001). The probable range in this study for a detectable change in ﬂ ushing 
symptoms (MID) was 0.29–0.38 points for mean overall ﬂ ushing severity and 0.41–
0.54 points for maximum overall ﬂ ushing severity. CONCLUSIONS: The FAST is a
new instrument designed to assess the symptoms and impact of niacin-induced ﬂ ush-
ing. The FAST exhibited test-retest reliability and substantial evidence of construct 
validity among patients with dyslipidemia. Overall, ﬂ ushing severity was responsive 
to change over time, suggesting that the FAST is a useful instrument for evaluating
ﬂ ushing symptoms induced by niacin therapy.
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OBJECTIVES: Measuring patients subjective health status (HS) has become accepted
in cardiology. However, the effect of these measurements on outcome and well-being
of heart failure patients remains unclear. METHODS: The aim of this study was to
investigate the impact of measuring HS on intermediate patients’ well-being. In two
Austrian heart failure outpatient wards 175 patients with documented heart failure 
were randomized into an intervention (IG) and control group (CG). Patients HS in
the IG was measured prior to the physician contact using the Short-Form 36 and 
Hospital Anxiety and Depression Scale. IG-patients received feedback electronically
feedback on their individual HS. The results were also made available to the treating 
physicians. They were encouraged to give additional feedback or to apply results for
auxiliary treatment planning (e.g., counselling). Patients in CG received usual care
without measuring HS prior to the physicians visit. After the visit, patients in both
groups rated their health-related quality of life (HRQL) and general health on the 
MacNew Heart Disease HRQL Instrument. Patients were reassessed by postal ques-
tionnaire six months after initial visit. RESULTS: Complete 6-month follow-up data
was available for 139 patients (79% response rate; 25.3% female; age: 58 o 13.2;
64.2% retired; NYHA I: 14.7%, NYHA II: 53.9%, NYHA III: 24.5%, NYHA IV: 
6.9%). Physical HRQL signiﬁ cantly deteriorated in both groups (IG: 0.3; CG: 0.4, 
both p  .01), whereas no signiﬁ cant deterioration for emotional and social HRQL 
was reported by the IG (IG: 0.1; 0.1, p  ns). Overall health improved in 34% of 
the IG patients, but only in 22% of the CG patients [ARR  12%, p  0.09; NNT of 
9]. CONCLUSIONS: Routine assessment of patients subjective HS appears to be
beneﬁ cial in helping maintain the well-being of heart failure patients (NNT  9), which 
naturally decreases over time. These results, however, need to be replicated in an ade-
quately powered study [N  211,á  .005, 1-â  0.89].
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EVALUATION OF COMPARATIVE EFFECTIVENESS: A MODEL FOR
GENERATING HYPOTHESES AND DETERMINING SAMPLE SIZE
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OBJECTIVES: Although payers are asking for comparative effectiveness data, risk of 
conducting studies is signiﬁ cant. One possible intermediary step is to leverage a vali-
dated instrument, the Treatment Satisfaction Questionnaire for Medication Version 
1.4 (TSQM), to identify domains for separation and calculate sample size required for 
superiority in a comparative study. METHODS: We used data from iGuard.org, a
consumer drug safety service totaling over 1 million members, whereby patients are
randomly invited to complete the TSQM on an on-going basis. TSQM is a 14-item 
reliable and valid instrument providing scores on four scales—effectiveness, side 
effects, convenience and global satisfaction. For this study, we analyzed all responses 
from patients using lisinopril and metoprolol. For sample size evaluation, adjusted 
means (LsMean) and standard errors (SE) were generated for each treatment using an 
analysis of covariance model controlling for: patient age; gender; self-reported severity 
of disease; and use of other hypertensive, diabetes and heart failure medications.
RESULTS: A total of 625 patients, 363 (58.1%) on lisinopril and 262 (41.9%) on 
metoprolol completed the TSQM between March and November 2008. TSQM
domains had good internal consistency with Cronbach’s alpha values over 0.85. There
were signiﬁ cant differences between the two treatments on age; self-reported severity; 
and use of diabetes and heart failure medications. LsMean (SE) for lisinopril and
metoprolol was 68.80 (1.46) and 66.01 (1.53) on effectiveness; 90.72 (1.83) and 85.66 
(1.91) on side effects; 87.09 (1.28) and 81.55 (1.34) on convenience; and 67.67 (1.78) 
and 62.92 (1.86) on global satisfaction, respectively. Given differences observed, a 
sample size of 640 per treatment would be required to detect a statistically signiﬁ cant
difference at a two-sided alpha of 0.05 with 80% power. CONCLUSIONS: This 
obtains feedback on comparative effectiveness study design and risk by conducting a
pre-study that administers a validated instrument to an on-line community.
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RANDOMIZED CLINICAL TRIAL
Winston RA1, Lu Z2, Shaya FT2, Laird A1, Saunders E3
1Bon Secours Baltimore Health System, Baltimore, MD, USA, 2University of Maryland School
of Pharmacy, Baltimore, MD, USA, 3University of Maryland School of Medicine, Baltimore, 
MD, USA
OBJECTIVES: The purpose of this study is to assess: 1) the impact of different educa-
tion modules (class education, mail education or both) on Hemoglobin A1c control 
in diabetic patients with hypertension; 2) determine which education module was the
most effective for patient disease process awareness based on Knowledge Tool Test
scores. METHODS: Adult patients with type-2 Diabetes with concomitant hyperten-
sion were recruited from community based primary care physician ofﬁ ces. The study 
was composed of 825 diabetic patients, a subset of those enrolled in the Baltimore 
Partnership Programs to Reduce CVD Disparities project based on a minimum of one 
year of follow-up. Intervention patients received education either by class, mail, or 
both. HbA1c was measured at baseline and patients were followed-up every six 
months. Multiple regression models were used to assess the effects of 1) Different 
education modules on HbA1c change, deﬁ ned as percent change of HbA1c from
baseline; 2) different education modules on change of patients’ disease process aware-
ness, deﬁ ned as change of Knowledge Tool Test score from the baseline. The model
was adjusted for sociodemographic variables. RESULTS: The majority of the diabetic 
patients were African American (88.61%), females (65.62%), and the mean age was
65 years. The mean HbA1c reduction was 0.8. As compared to the control patients 
(0.7), the HbA1c reduction was larger in intervention patients (0.9). Males (0.82 
vs. 0.78) had a higher reduction in HbA1c values than females. Opposite trends were
found on patient disease process awareness. CONCLUSIONS: In this patient sample,
decreased trend in HbA1c level and an increased trend in Knowledge Tool Test score 
is seen among intervention patients, with class education module being more effective 
in patient disease process awareness. These results may help guide future patient
intervention programs for diabetes and hypertension management.
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OBJECTIVES: Consumer directed health plans (CDHP) are aimed at reducing moral
hazard due to insurance coverage. How do CDHP plans affect the consumption of 
pharmaceuticals for chronic diseases such as hypertension, high cholesterol and
diabetes? METHODS: We obtained data on all employees from a large private U.S.
employer for the 2005 to 2007 time period. All enrollees in the CDHP plan in this 
study are initially provided an employer funded Health Reimbursement Account 
(HRA) from which they can purchase medical care. Funds in these accounts range
from $1000 to $2000 depending on whether the enrollee is in an individual or a family 
health plan. After the HRA funds are exhausted, there is a second phase in which 
enrollee spending is completely out of pocket (range from $500 to $2000), after which
time the insurance plan begins coverage. We compare average daily pharmaceutical 
spending for individuals with diabetes, hypertension and high cholesterol as they move
through each of the different coverage thresholds(HRA, Out-of-Pocket and Full-
Coverage). RESULTS: Using Icd-9 codes we identiﬁ ed 27,644 individuals diagnosed
with diabetes, hypertension or high-cholesterol. For each of these diseases average 
daily pharmaceutical expenditure was substantially lower when individuals were in
the HRA and out-of-pocket sections of their CDHP plan as compared to when they 
were in the Full-Coverage part of their insurance plan. Average daily expenditure on 
pharmaceuticals was approximately $2.60 for individuals in the HRA section of the 
plan, $1.00 for individuals who moved into the out-of-pocket part of the insurance 
plan and $4.00 for individuals who were covered by insurance. CONCLUSIONS:
Findings from this study suggest that cost-sharing levels in CDHP plans affect phar-
maceutical spending on the treatment of chronic diseases. Reductions in chronic
disease pharmaceutical expenditures have the potential to negatively affect enrollee
health outcomes.
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OBJECTIVES: Discover if age-, gender-, race-, or income-related disparities in care 
for coronary artery disease (CAD) exist among Medicare enrollees with supplement 
plan coverage (i.e. Medigap). METHODS: Data were obtained from UnitedHealth
Group’s database of AARP Medigap enrollees. Patients were selected into the study 
if they had one or more medical claims with a diagnosis of CAD from July 1, 2006-
June 30, 2007. Logistic regression analyses tested for age-, gender-, race-, or income-
related differences in the likelihood of receiving an ofﬁ ce visit, coronary angiography,
or surgical intervention. The regression models controlled for socioeconomics, health 
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status, type of supplement plan, and residential location. RESULTS: Of the 2.2 million 
Medigap insureds eligible for the study, 25.4% (570,711) had CAD. Males were 60%
(p  0.001) more likely than females to have an ofﬁ ce visit, but gender was not a sig-
niﬁ cant predictor for the other services. Patients residing in high-minority neighbor-
hoods were about 8% (p  0.001) less likely to receive any services for CAD. Older 
individuals were signiﬁ cantly less likely (p  0.001) to have invasive procedures 
(angiography and surgery). Patients residing in lower-income areas were about 9% (p 
 0.001) more likely to receive any of the CAD services. Patients with mental health
problems were about 45% (p  0.001) less likely to receive any CAD services. Addi-
tionally, CAD-related care varied signiﬁ cantly by state of residence and urban versus 
rural location. Insureds with policies that covered more out-of-pocket costs were more 
likely to receive an ofﬁ ce visit, however, policy type was not a signiﬁ cant predictor for 
invasive CAD procedures. CONCLUSIONS: Disparities in CAD-related care existed 
by age, income, and race, but the magnitude was relatively small (about 10%). Larger 
disparities were found by residential location and for those with mental health prob-
lems. AARP and UnitedHealth Group are designing interventions to address these
disparities; such interventions will begin in mid-2009.
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HOW DOES THE OUT-OF-POCKET PAYMENT MATTER TO
HYPERTENSIVE PATIENTS’ CHOICES OF ACCESSING DIFFERENT
MEDICAL FACILITIES IN TAIWAN? THE PRELIMINARY STUDY OF A
DISCRETE CHOICE EXPERIMENT
Lee YY, Chen LC, Lee CJ, Lee CS
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OBJECTIVES: With generous coverage and patients’ full freedom to access different
tiers of medical facilities, Taiwan’s single payer national health insurance system is 
facing difﬁ culties of escalating utilization and cost of out-patient care. Recently, out-
patient co-payment has been largely increased in order to control unnecessary medical
demands and encourage patients with minor illness of initial contact in primary care,
but this policy has only shown limited impacts. To determine the relative importance 
of factors (attributes) associated with patients’ choices on accessing different tiers of 
medical facilities, we conducted a qualitative study on hypertensive outpatients.
METHODS: Focus groups were conducted on hypertensive outpatients from different 
tiers (clinics, local, regional hospitals and medical centers) of medical facilities in
Southern Taiwan. RESULTS: Nine focus groups were conducted at local community
(1), local hospital (2), regional hospital (2) and medical center (4), including 40 
hypertensive participants. The saturated opinions indicated doctors’ reputation and
friendliness, tiers of hospitals, and transportation convenience as the three main con-
siderations for participants to access different hospitals. Participants tend to visit a
ﬁ xed doctors and hospitals because they believe hypertension needs a long-term, con-
secutive and quality treatment. Higher-tier medical facilities are symbolized as better 
medical care, drugs and equipments, yet the out-of-pocket payment is considered
affordable, especially doctors prescribed continuous prescriptions to save patient’s
co-payment charge. Participants dislike being transferred from lower to higher tiers
of medical facilities due to the inconvenient process and lack of price incentive. 
CONCLUSIONS: By identifying attributes to hypertensive outpatients’ choices of 
accessing medical facilities, we found the current co-payment policy does not impact 
on hypertensive patients’ affordability and accessibility in Southern Taiwan. Future
study is going to determine the relative importance of attributes and whether and how
much higher co-payment charge can inﬂ uence on patients’ decisions to access different
tiers of medical facilities.
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OBJECTIVES: Top describe the tendency of cardiovascular risk and the determining 
factors of a cohort of patients enrolled in the De todo corazón disease management 
(DM) programme. METHODS: The DTC programme was begun in Colombia in
2004 and 19,697 patients have beneﬁ tted up to December 2007; it seeks to control 
cardiovascular risk (CVR) using a DM model. The present study represents a ﬁ rst 
approach to evaluate the programme’s effectiveness by analysing the tendency of CVR 
marker variables, such as blood-pressure and lipid proﬁ le by CVR group. The popula-
tion being studied consisted of patients who had formed part of the programme since
2004 and who had uninterrupted annual follow-up visits up to 2007. A descriptive
analysis was made, annual CVR level was calculated using the methodology described 
by ATPIII and tendency was described by both variables and CVR groups. RESULTS:
Average age for the ﬁ nal population to be analysed (5174) was 63.74 years (11.76 
S.D) and mainly consisted of females (72%). A decreasing tendency in the high risk 
group was observed in analysis by CVR group, accompanied by a corresponding
increase in patients classiﬁ ed in latent and intermediate levels. Similarly, analysing 
tendency by variable revealed how systolic blood-pressure tended to decrease consis-
tently throughout the time spent on each visit in each risk group. LDL-cholesterol
revealed a similar tendency in high and intermediate risk groups, less stable behaviour
being seen in the latent risk group. HDL-cholesterol presented stable tendency in the 
three risk groups during successive visits. CONCLUSIONS: The results suggested that 
the De todo corazón DM programme had a positive impact during the period being 
studied, affecting modiﬁ able risk factors such as TA and lipid proﬁ le and CVR control. 
Such tendencies should be compared with a control group for establishing whether 
they have really been produced by the DM programme.
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OBJECTIVES: This study compared hypertension management in newly treated and
previously treated (established) adult patients (q18 years) with hypertension. 
METHODS: A retrospective study was conducted using the GE Centricity electronic 
medical record database which contains ambulatory electronic health record data for 
over 7.4 million patients in the US. Patients were classiﬁ ed as newly treated hyperten-
sives if they had no antihypertensive treatment within 24 months prior to the index 
date (date of the ﬁ rst anti-hypertensive prescription in 2006). Otherwise, patients were 
classiﬁ ed as established hypertensives if they received antihypertensive treatment
during 24 months prior to index date. These two groups were compared to assess 
differences in comorbid conditions, proportion of patients treated per JNC-7 guide-
lines, distribution of index drugs, likelihood of achieving BP goal and changes in the 
antihypertensive therapy during 13 months follow-up period from the index date. 
RESULTS: A total of 28,276 newly treated patients (mean age 58.6 years; 55.7% 
women) and 78,450 (62.1 years; 57.1% women) established patients were identiﬁ ed. 
Newly diagnosed patients had fewer comorbidities (mean number 0.74 vs. 1.85; p 
0.001), less changes in anti-hypertensive medications (1.6 vs. 1.7; p  0.001), less 
likely to be treated per JNC-7 guideline (52.7% vs. 60.2%; p  0.001), and more
likely to be treated on monotherapy at index (66.2% vs. 39.9%; p  0.001) than 
established patients. Among the newly diagnosed patients, ACE inhibitors (ACEi) 
(30.6%) and diuretics (19.2%) were the most commonly prescribed ﬁ rst-line treat-
ments, while ACEi (22.3%) and the combination of ACEi and diuretics (9.2%) were 
more commonly prescribed in the established patients. After controlling for age,
gender, race, comorbid conditions, baseline BP, adherence to JNC-7, newly diagnosed
patients were 38% more likely to achieve BP goal at follow-up (p  0.001). CONCLU-
SIONS: Newly treated hypertensive patients tend to be younger, with less comorbidi-
ties, more likely to be treated on monotherapy and achieve BP goal compared with 
established patients.
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ELECTRONIC MEDICAL RECORD USE AND WARFARIN DRUG-DRUG 
INTERACTIONS DURING AMBULATORY VISITS IN THE UNITED STATES, 
2003–2006
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OBJECTIVES: Elevated warfarin levels caused by drug-drug interactions (DDIs) 
increase the risk of gastrointestinal bleeding and vascular accidents. Electronic medical 
records (EMRs) have been associated with a greater potential for identifying DDIs.
We evaluated the inﬂ uence of EMR use on trends in prescribing potentially harmful
drug combinations involving warfarin from a nationwide survey of ambulatory care 
ofﬁ ce visits. METHODS: Data were derived from the 2003–2006 National Ambula-
tory Medical Care Survey (NAMCS), a public-use, nationwide probability sample 
survey of ofﬁ ce visits by ambulatory patients to non-Federally employed physicians. 
Warfarin and interacting drugs prescribed within the same visit were identiﬁ ed. We 
evaluated the proportion of interaction-related encounters comparing visits with and
without the availability of EMRs. Subgroup analyses were performed by combining
2-years of data (2003–2004 and 2005–2006) for more precise estimates. All analyses
were weighted to reﬂ ect the sampling design of NAMCS to reﬂ ect representative 
ambulatory care use in the U.S. with appropriate variances. RESULTS: Total warfarin-
related visits increased from 11.8 million in 2003 to 16.6 and 15.4 million in 2005 
and 2006, respectively. In 2003–2004 (period 1) the proportion of warfarin visits in 
which an interacting drug was co-prescribed was 34.4% (95% CI: 21.4%–47.4%) 
with EMRs available and 32.0% (95% CI: 27.5%–36.5%) with no EMRs available. 
In 2005–2006 (period 2), the proportions were 36.7% (30.9%–42.4%) with EMRs 
and 33.5% (28.6%–38.3%) without EMRs. We observed no signiﬁ cant differences in 
the proportions of interaction-related encounters between EMR and non-EMR visits 
in both periods. CONCLUSIONS: Between 2003 and 2006, the rates of warfarin
prescribing in ambulatory care increased by 27%. The proportions of interaction-
related encounters were unaffected by EMR use, due possibly to the limited imple-
mentation of EMRs during that period. Further studies as newer data become available
are needed.
